Bio-Techne Crecimiento futuro
Future controles de criterios 1/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Bio-Techne de 10.2% y 7.6% por año respectivamente. Se prevé que el BPA crezca en un 9.7% al año. Se espera que la rentabilidad financiera sea de 14.3% en 3 años.
Información clave
10.2%
Tasa de crecimiento de los beneficios
9.7%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Life Sciences | 16.4% |
| Tasa de crecimiento de los ingresos | 7.6% |
| Rentabilidad financiera futura | 14.3% |
| Cobertura de analistas | Good |
| Última actualización | 29 Apr 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Bio-Techne Corporation (NASDAQ:TECH) Shares Could Be 32% Above Their Intrinsic Value Estimate
Apr 15
Bio-Techne: Secular Growth Opportunities Always Exhibit Financial Excellence
Apr 04We Think Bio-Techne (NASDAQ:TECH) Can Stay On Top Of Its Debt
Jan 17Bio-Techne Corporation (NASDAQ:TECH) Investors Are Less Pessimistic Than Expected
Dec 30Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Dec 05Is Now An Opportune Moment To Examine Bio-Techne Corporation (NASDAQ:TECH)?
Oct 10Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet
Sep 22A Look At The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Sep 01At US$80.80, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?
Jul 10Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?
Jun 22With EPS Growth And More, Bio-Techne (NASDAQ:TECH) Makes An Interesting Case
Jun 07Bio-Techne Corporation's (NASDAQ:TECH) Intrinsic Value Is Potentially 25% Below Its Share Price
May 23When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?
Apr 05Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet
Mar 21Here's Why We Think Bio-Techne (NASDAQ:TECH) Is Well Worth Watching
Mar 06When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?
Jan 03We Think Bio-Techne (NASDAQ:TECH) Can Manage Its Debt With Ease
Dec 15Should You Be Adding Bio-Techne (NASDAQ:TECH) To Your Watchlist Today?
Nov 30Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Nov 17Bio-Techne releases new AVV viral titer assays
Oct 11At US$291, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?
Sep 26Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?
Sep 12Bio-Techne to seek shareholder approval for 4- for-1 stock split
Sep 01Is Now The Time To Put Bio-Techne (NASDAQ:TECH) On Your Watchlist?
Aug 29Bio-Techne releases Quantist Luminex data analysis software
Aug 18Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Aug 16Bio-Teche announces transition plan for CEO Kummeth
Aug 04Bio-Techne: Resiliency Comes At A Large Premium
Jul 29Bio-Techne launches HPV detection test RNAscope in Europe for use in throat cancer
Jul 06Should You Think About Buying Bio-Techne Corporation (NASDAQ:TECH) Now?
Jun 22Is Bio-Techne (NASDAQ:TECH) Using Too Much Debt?
Jun 09Is Now The Time To Put Bio-Techne (NASDAQ:TECH) On Your Watchlist?
May 26Estimating The Fair Value Of Bio-Techne Corporation (NASDAQ:TECH)
May 13Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 6/30/2026 | 1,380 | 268 | 349 | 404 | 10 |
| 6/30/2025 | 1,245 | 229 | 332 | 386 | 12 |
| 6/30/2024 | 1,146 | 179 | 263 | 315 | 13 |
| 12/31/2023 | 1,145 | 224 | 225 | 276 | N/A |
| 9/30/2023 | 1,144 | 247 | 215 | 258 | N/A |
| 6/30/2023 | 1,137 | 285 | 216 | 254 | N/A |
| 3/31/2023 | 1,124 | 271 | 233 | 274 | N/A |
| 12/31/2022 | 1,120 | 262 | 252 | 296 | N/A |
| 9/30/2022 | 1,118 | 292 | 285 | 333 | N/A |
| 6/30/2022 | 1,106 | 272 | 280 | 325 | N/A |
| 3/31/2022 | 1,076 | 225 | 302 | 345 | N/A |
| 12/31/2021 | 1,030 | 210 | 308 | 346 | N/A |
| 9/30/2021 | 985 | 177 | 295 | 335 | N/A |
| 6/30/2021 | 931 | 140 | 308 | 352 | N/A |
| 3/31/2021 | 848 | 184 | 225 | 275 | N/A |
| 12/31/2020 | 799 | 175 | 201 | 250 | N/A |
| 9/30/2020 | 760 | 248 | 179 | 231 | N/A |
| 6/30/2020 | 739 | 229 | 153 | 205 | N/A |
| 3/31/2020 | 755 | 187 | 170 | 216 | N/A |
| 12/31/2019 | 745 | 195 | 165 | 207 | N/A |
| 9/30/2019 | 734 | 93 | 151 | 183 | N/A |
| 6/30/2019 | 714 | 96 | 156 | 182 | N/A |
| 3/31/2019 | 703 | 121 | 171 | 191 | N/A |
| 12/31/2018 | 682 | 96 | 154 | 173 | N/A |
| 9/30/2018 | 661 | 128 | 145 | 165 | N/A |
| 6/30/2018 | 643 | 126 | 149 | 170 | N/A |
| 3/31/2018 | 619 | 112 | 135 | 156 | N/A |
| 12/31/2017 | 599 | 114 | 138 | 160 | N/A |
| 9/30/2017 | 577 | 73 | N/A | 162 | N/A |
| 6/30/2017 | 563 | 76 | N/A | 144 | N/A |
| 3/31/2017 | 541 | 74 | N/A | 129 | N/A |
| 12/31/2016 | 528 | 82 | N/A | 141 | N/A |
| 9/30/2016 | 517 | 101 | N/A | 138 | N/A |
| 6/30/2016 | 499 | 104 | N/A | 144 | N/A |
| 3/31/2016 | 482 | 105 | N/A | 145 | N/A |
| 12/31/2015 | 465 | 99 | N/A | 138 | N/A |
| 9/30/2015 | 456 | 107 | N/A | 135 | N/A |
| 6/30/2015 | 452 | 108 | N/A | 139 | N/A |
| 3/31/2015 | 427 | 108 | N/A | 140 | N/A |
| 12/31/2014 | 408 | 116 | N/A | 144 | N/A |
| 9/30/2014 | 380 | 107 | N/A | 140 | N/A |
| 6/30/2014 | 358 | 111 | N/A | 137 | N/A |
| 3/31/2014 | 345 | 113 | N/A | 129 | N/A |
| 12/31/2013 | 330 | 114 | N/A | 127 | N/A |
| 9/30/2013 | 321 | 114 | N/A | 127 | N/A |
| 6/30/2013 | 311 | 113 | N/A | 124 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (10.2% al año) de TECH es superior a la tasa de ahorro (2.3%).
Beneficios vs. Mercado: Se prevé que los beneficios (10.2% al año) de TECH crezcan menos que el mercado US (14.7% al año).
Beneficios de alto crecimiento: Se prevé que los beneficios de TECH crezcan, pero no significativamente.
Ingresos vs. Mercado: Se prevé que los ingresos (7.6% al año) de TECH crezcan más despacio que el mercado de US (8.1% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 7.6% al año) de TECH crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de TECH sea baja dentro de 3 años (14.3%).